Effectiveness and Implications of Alternative Placebo Treatments A Systematic Review and Network Meta-analysis of Osteoarthritis Trials

被引:145
作者
Bannuru, Raveendhara R.
McAlindon, Timothy E.
Sullivan, Matthew C.
Wong, John B.
Kent, David M.
Schmid, Christopher H.
机构
[1] Tufts Univ, Sackler Sch Grad Biomed Sci, Tufts Med Ctr, Boston, MA 02111 USA
[2] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA
基金
美国医疗保健研究与质量局;
关键词
INTRAARTICULAR HYALURONIC-ACID; TOPICAL DICLOFENAC SOLUTION; RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED CLINICAL-TRIAL; HYLAN G-F-20 SYNVISC(R); ETORICOXIB; 30; MG; CELECOXIB; 200; QUALITY-OF-LIFE; VEHICLE TDT 064;
D O I
10.7326/M15-0623
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Placebo controls are essential in evaluating the effectiveness of medical treatments. Although it is unclear whether different placebo interventions for osteoarthritis vary in efficacy, systematic differences would substantially affect interpretation of the results of placebo-controlled trials. Objective: To evaluate the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Data Sources: MEDLINE, EMBASE, Web of Science, Google Scholar, and Cochrane Database from inception through 1 June 2015 and unpublished data. Study Selection: 149 randomized trials of adults with knee osteoarthritis that reported pain outcomes and compared widely used pharmaceuticals against oral, intra-articular, topical, and oral plus topical placebos. Data Extraction: Study data were independently double-extracted; study quality was assessed by using the Cochrane risk of bias tool. Data Synthesis: Placebo effects that were evaluated by using a network meta-analysis with 4 separate placebo nodes (differential model) showed that intra-articular placebo (effect size, 0.29 [95% credible interval, 0.09 to 0.49]) and topical placebo (effect size, 0.20 [credible interval, 0.02 to 0.38]) had significantly greater effect sizes than did oral placebo. This differential model showed marked differences in the relative efficacies and hierarchy of the active treatments compared with a network model that considered all placebos equivalent. In the model accounting for differential effects, intra-articular and topical therapies were superior to oral treatments in reducing pain. When these differential effects were ignored, oral nonsteroidal anti-inflammatory drugs were superior. Limitations: Few studies compared different placebos directly. The study could not decisively conclude whether disease severity and co-interventions systematically differed between trials evaluating different placebos. Conclusion: All placebos are not equal, and some can trigger clinically relevant responses. Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments, an important consideration for the design of clinical trials and interpretation of their results.
引用
收藏
页码:365 / U109
页数:28
相关论文
共 180 条
[1]
The role of viscosupplenentation with hylan G-F 20 (Synvisc(R)) in the treatment of osteoarthritis of the knee: A Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone [J].
Adams, ME ;
Atkinson, MH ;
Lussier, AJ ;
Schulz, JI ;
Siminovitch, KA ;
Wade, JP ;
Zummer, M .
OSTEOARTHRITIS AND CARTILAGE, 1995, 3 (04) :213-225
[2]
Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study [J].
Altman, R. D. ;
Zinsenheim, J. R. ;
Temple, A. R. ;
Schweinle, J. E. .
OSTEOARTHRITIS AND CARTILAGE, 2007, 15 (04) :454-461
[3]
Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee [J].
Altman, RD ;
Åkermark, C ;
Beaulieu, AD ;
Schnitzer, T .
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 (08) :642-649
[4]
Altman RD, 1998, J RHEUMATOL, V25, P2203
[5]
A Double-Blind, Randomized, Saline-Controlled Study of the Efficacy and Safety of EUFLEXXA® for Treatment of Painful Osteoarthritis of the Knee, With an Open-Label Safety Extension (The FLEXX Trial) [J].
Altman, Roy D. ;
Rosen, Jeffrey E. ;
Bloch, Daniel A. ;
Hatoum, Hind T. ;
Korner, Paul .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2009, 39 (01) :1-9
[6]
[Anonymous], 2014, OST CAR MAN AD
[7]
[Anonymous], SODIUM HYALURONATE S
[8]
[Anonymous], DOUBL BLIND RAND TRI
[9]
A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis [J].
Arden, Nigel K. ;
Akermark, Christian ;
Andersson, Mats ;
Todman, Martin G. ;
Altman, Roy D. .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (02) :279-286
[10]
EFFICACY AND TOLERABILITY OF CELECOXIB IN PATIENTS WITH OSTEOARTHRITIS WHO PREVIOUSLY DID NOT RESPOND TO OR DID NOT TOLERATE NAPROXEN AND IBUPROFEN: RESULTS FROM 2 IDENTICALLY DESIGNED RANDOMIZED TRIALS [J].
Asmus, M. J. ;
Essex, M. N. ;
Brown, P. Bhadra ;
Mallen, S. R. .
OSTEOARTHRITIS AND CARTILAGE, 2013, 21 :S253-S253